Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Of sixty patients with chronic liver disease, eight with cirrhosis or chronic hepatitis had very low serum CH50 but normal plasma CH50. The complement component profiles of these sera revealed markedly decreased C4 and C2 activities and normal C3T (C3-C9) activities. From these results, it is suggested that the early acting complement components had been non-specifically activated during blood coagulation in these patients. No difference between plasma and serum CH50 was found in patients with hepatitis B(s) antigen.
 ...
PMID:Differences between plasma and serum complement in patients with chronic liver disease. 96 9

To document the sequelae of acute hepatitis among recipients of commercial and volunteer blood and to assess factors influencing the development of chronic hepatitis (CH), 47 patients with post-transfusion hepatitis were followed prospectively from the time they received their transfusions. Twenty-nine had prolongation of at least 2-fold serum glutamic pyruvic transaminase (T) elevations for more than 20 weeks, and were classified as CH. When the patients with CH were compared to those with only acute hepatitis (abnormal T for less that 20 weeks), no difference was found with respect to age, sex, number of units transfused, incubation period, presence or absence of symptoms, occurrence of jaundice, maximum T, receipt or development of hepatitis B surface antigen or antibody, underlying illness, or area of the hospital where the patient was treated. Liver biopsies in 15 of the 29 revealed chronic-active hepatitis in 9, chronic persistent hepatitis in 2, unresolved hepatitis in 4. Five of the 9 patients with chronic active hepatitis were without symptoms. None of these died or have developed cirrhosis. Because chronic liver disease frequently developed after acute post-transfusion hepatitis among multiply transfused hepatitis B surface antigen negative blood recipients, close follow-up, including liver biopsy, is warranted in such patients with prolonged transaminase elevations.
 ...
PMID:Post-transfusion chronic liver disease. 96 71

In 1488 cases of chronic liver disease thrombocyte content of peripheral blood, clinical diagnosis and histologic findings of the liver biopsy were correlated. Ranging from fatty infiltration to fatty cirrhosis or from slightly active chronic hepatitis to active postnecrotic cirrhosis, according to the extent of the liver injury a significant decrease of thrombocyte-count was evaluated. In case of non-active liver disease and posthepatitic status a thrombocytopenia also could be found. Cirrhotic transformation or proliferation of the connective tissue mainly in the periportal fields and inflammatory activity showed a significant correlation to the frequency of a thrombocyte decrease. A pathogenetic relation is ascribed to an increased thrombocyte storage in the spleen depending on the extent of the liver injury and the alteration of the portal blood stream up to a portal hypertension. Our results indicate such correlations of liver injury, portal pressure and platelet-pooling to thrombocyte-count even if the causal dependency cannot be proved.
 ...
PMID:[Corelations between thrombocyte count, clinical diagnosis, and liver pathology in chronic liver diseases]. 96 86

Factor VII levels have been measured in 100 patients with liver disease following parenteral vitamin K1 therapy. There was good agreement between specific factor VII measurements and the one-stage prothrombin time apart from six patients with compensated cirrhosis in whom the prothrombin time was prolonged despite the presence of normal factor VII levels. A mean activity of 58% was found in patients with cirrhosis. Cirrhotic patients with features of hepatic decompensation had a significantly lower mean level of activity (40%) than the "contrast" patients with surgical obstruction of the major bile ducts (93%). Patients with chronic active liver disease had moderate depression of factor VII levels and those with non-cirrhotic liver damage had mean activities similar to the contrast group. Factor VII levels could not be correlated with BSP retention but there was a correlation with serum albumin concentration. It is concluded that the prothrombin time using Quick test with a standardized thromboplastin showing good sensitivity to factor VII, eg, the Manchester reagent (BCT), provides a reliable index of coagulability in chronic liver disease, and specific factor VII assays are not indicated.
 ...
PMID:Factor VII as a marker of hepatocellular synthetic function in liver disease. 100 40

Patients with chronic liver disease were tested for delayed hypersensitivity to the outer and the inner membranes of mitochondria (OMM and IMM) and the insoluble hepatocyte-surface membranes (IHSM), prepared from rat livers, by means of leucocyte migration inhibition technique. Positive reaction to OMM was found in 37% of patients with chronic persistent hepatitis and 35% of those with chronic active hepatitis and 43% of those with liver cirrhosis (P less than 0-05). That to IMM was 55%, 43% and 36% (P less than 0-05) and to IHSM was 37%, 47% and 45% respectively (P less than 0-05). IHSM was found to contain liver-specific components and patients with positive response to IHSM did not reveal at all a positive reaction to rat renal cell-surface membranes. The incidence of positive response to IHSM was significantly higher (54-2%) in patients with the present or previous infection with HBAg than in HBAg-non-infected patients (21-4%) (P less than 0-05). And there seemed to be a good correlation between a degree of cellular response to purified HBsAg and that to IHSM in these HBAg-infected patients. No correlation, however, was found between that to purified HBsAg and that to OMM or IMM in the same patients. This suggested that the cellular response to either HBsAg or IHSM, both related closely, may play a role in the perpetuation of chronic liver disease.
 ...
PMID:Leucocyte migration inhibition with inner and outer membranes of mitochondria and insoluble hepatocyte surface membranes prepared from rat liver in patients with chronic hepatitis and cirrhosis. 100 83

A recently introduced clotting test designed for the assessment of liver insufficiency was used in 10 normal subjects, 10 with toxic liver disease, 10 with chronic liver disease, and 10 with chronic liver disease, and 10 with cirrhosis of the liver. Comparison with the results of Quick's test, Normotest and thrombotest showed the new test to have excellent standardisation and good sensitivity in the detection of liver impairment.
 ...
PMID:[Clinical evaluation in liver diseases of a new blood coagulation test for the determination of factors II, VII and X]. 102 39

Serum cholesterol, triglyceride, total lipids and the lipoprotein pattern were studied in 169 cases chronic liver disease confirmed by biopsy. On the ground of the immunological and morphological results the patients were classified into five groups. In chronic persistent hepatitis no significant abnormality was found. In chronic aggressive hepatitis and in cirrhosis of the liver the serum cholesterol level was significantly reduced. In fatty infiltration of the liver the serum cholesterol, triglyceride and total lipid concentrations were significantly increased, as compared with the normal values and with the figures obtained in the cases of chronic inflammatory liver disease. In the cases of cirrhosis with additional diabetes the lipid values were likewise increased. In chronic aggressive hepatitis and in cirrhosis of the liver the levels of pre-beta and alpha lipoprotein were decreased, in fatty infiltration of the liver those of beta and pre-beta lipoprotein were increased.
 ...
PMID:Serum lipids and lipoproteins in chronic liver disease. 103 49

The AusRIA 2 test has been modified for HBs antibody detection. This technique is about 7 to 8 dilution steps more sensitive for antibody detection than the IPE. Using this modified radioimmunological technique investigations have been carried out on blood donors, patients with acute and chronic liver disease and on haemophiliacs. An HBs antibody incidence of 11% was found among voluntary blood donors. Intensive clinical investigation of blood donors positive for HBs antibodies by IPE demonstrated that the Serum GOT was elevated in 11% of cases and the liver biopsy showed histological changes of different severity in 16 out of 22 cases. Investigation of 22 cases of acute HBs antigen-positive hepatitis confirmed that nearly all the patients developed HBs antibodies within 10 weeks following the disappearance of HBs antigen. The HBs antibodies persist over years. The appearance of HBs antibodies after an acute HBs antigen-negative hepatitis can be taken as an indication of a hepatitis-B virus infection also in these cases. Among 22 HBs antigen-negative chronic hepatitis cases, HBs antibodies were detectable in 52%. Sera of 111 patients with HBs antigen-negative liver cirrhosis of varying aetiology showed HBs antibodies in 29.7% of cases. The incidence was higher in males. HBs antibodies were found in 98% of patients with haemophilia. These results reveal new aspects with regard to the importance of the hepatitis-B viurs, especially in chronic liver disease. Apart from a description of the newly-developed HBs antibody test and a discussion of the results obtained using this technique, a survey is given of the importance of HBs antibody determination by means of sensitive methods for clinical and epidemiological purposes.
 ...
PMID:[Hepatitis-B-surface-antibodies (detection, incidence, clinical importance)]. 106 4

A prothrombin complex concentrate was used in attempts to control life-threatening hemorrhage in 4 patients with chronic liver disease. The population manifested profuse bleeding from varices and/or hemorrhagic gastritis; 3 had Laennec's cirrhosis and 1 had postnecrotic cirrhosis from childhood hepatitis. In all patients the complex was given in amounts needed to raise the prothrombin (factor II) level to approximately 100% of normal. In all 4 cases the prothrombin time and prothrombin complex factors approached normal within 1-2 hr after beginning the infusion. In all patients bleeding ceased with correction of the clotting status. One patient rebled several hours after completing the infusion. In several patients, increases in factors V and VIII were noted following infusion of the concentrate. A further unexpected finding was a spontaneous increase in factors II and IX at 3 days postinfusion. Prothrombin complex concentrate appears to be useful in controlling the hemorrhage of chronic liver disease when used alone or in combination with other modalities to correct specific hemostatic defects; however, patients may be expected to rebleed when the effect of the concentrate wears off. Its use, therefore, should probably be restricted to those patients who are to undergo corrective surgery of the bleeding point once hemostasis is achieved.
 ...
PMID:Prothrombin complex concentrate: use in controlling the hemorrhagic diathesis of chronic liver disease. 108 Mar 55

Sera were tested for autoantibodies in 98 patients with cryptogenic cirrhosis in Uganda and results correlated with serological tests for hepatitis B surface antigen (HBs Ag) and antibody to HBs Ag (HBs Ab). Smooth muscle antibodies (SMA) were detected in 23 (24%) of the patients but there was no difference in the incidence of SMA between HBs Ag-positive and negative cases. Antinuclear antibodies (ANA) were detected in five cases; mitochondrial, gastric and thyroid antibodies were not found in any patient. Unlike other geographical locations autoimmune mechanisms appear to play little part in the progression of chronic liver disease in Uganda Africans. Hepatitis B surface antigen was present in 36 (37%) and HBs Ab in 47 (48%) of the patients. Although evidence for past exposure to hepatitis B virus (as shown by detection of HBs Ab) was present in at least 30 out of the 62 HBs Ag-negative cases, there was no greater incidence of autoantibodies in HBs Ag-negative patients with or without HBs Ab. Persistent infection with hepatitis B virus and continuing liver damage may be an important factor but these results do not favor a role for the virus in causing chronic liver disease by triggering off an autoimmune reaction.
 ...
PMID:Autoimmune factors in African cirrhosis. Correlation with hepatitis B surface antigen and antibody. 108 41


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>